VBI-2902

N VBI-2902 is a COVID-19 vaccine candidate developed by Variation Biotechnologies from the United States.

[2] In early 2020, in collaboration with NRC the VBI's vaccine—VBI-2900—was developed.

According to the company, they have two vaccine candidates—"enveloped virus-like particle (eVLP)".

[3] VBI-2901 is a "trivalent pan-coronavirus vaccine expressing the SARS-CoV-2, SARS-CoV, and MERS-CoV spike proteins".

[3][4][5] VBI received CA$56 million from the federal government towards the COVID-19 vaccine development.

Scientifically accurate atomic model of the external structure of SARS-CoV-2. Each "ball" is an atom.
Scientifically accurate atomic model of the external structure of SARS-CoV-2. Each "ball" is an atom.